The Animal Core will continue to provide investigators of each project with assistance in the conduct of research involving animals. The core will provide a focus of expertise that is germane to all projects and also efficiently utilize valuable resources. The core's PI, Dr. E. Keller has extensive experience with prostate cancer xenograft development and rodent models of prostate cancer including intratibial and intracardiac injection models. Dr. Keller will oversee the scientific direction of the core. The core's day-to-day activities will be overseen by Dr. Jill Keller, an American College of Laboratory Animal Medicine certified veterinarian. The Animal Core activities include: - Creating animal models to be used for the projects. For example, implantation of vertebrae of mice to create vossicle models will be performed by the Animal Core. - Assisting with animal experiments. Core personnel will coordinate and assist or instruct in the performance of standardized procedures such as intratibial and intracardiac injection, anesthesia, etc. Providing imaging capability for animal studies. The core will perform faxitron radiographs, bone densitometry (Dexa or pQCT), and bioluminescence. - Maintaining breeding colonies for various specialized mice as required for various projects. Specific genetically-modified mice will be maintained as required. - Development of new animal models of bone metastasis. Dr. J. Keller will test xenografts and cell lines derived from the Prostate SPORE for their ability to serve as models of skeletal metastasis.

Public Health Relevance

Bone metastasis are a serious and frequent clinical complication of prostate cancer. This core will provide animal models to help identify mechanisms and targets to attack this important aspect of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA093900-09
Application #
8377426
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
9
Fiscal Year
2012
Total Cost
$337,743
Indirect Cost
$75,933
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Axelrod, Haley D; Pienta, Kenneth J; Valkenburg, Kenneth C (2018) Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. Biol Proced Online 20:13
Jung, Younghun; Cackowski, Frank C; Yumoto, Kenji et al. (2018) CXCL12? Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res 78:2026-2039
Decker, A M; Taichman, L S; D'Silva, N J et al. (2018) Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 5:7-12
Miller, Dannah R; Tzeng, Cherng-Chyi; Farmer, Trey et al. (2018) Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Lett 436:96-108
Machioka, Kazuaki; Izumi, Kouji; Kadono, Yoshifumi et al. (2018) Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9:16185-16196
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266

Showing the most recent 10 out of 228 publications